Eli Lilly (LLY) saw its IBD SmartSelect Composite Rating jump to 96 Monday, up from 94 the day before. The new score tells you the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Eli Lilly is now out of buy range after clearing the 218.10 entry in a cup without handle.
Eli Lilly stock has an 88 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 88% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q2, Eli Lilly reported 29% earnings growth. Top line growth increased 23%, up from 16% in the prior quarter. That marks one quarter of accelerating revenue increases.
Eli Lilly holds the No. 2 rank among its peers in the Medical-Diversified industry group. Danaher (DHR) is the No. 1-ranked stock within the group.
YOU MIGHT ALSO LIKE: